Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

Radio Pharming !

45.610 Posts
Pagina: «« 1 ... 2088 2089 2090 2091 2092 ... 2281 »» | Laatste | Omlaag ↓
  1. forum rang 7 Jager63 3 augustus 2023 07:19

    • Jager63

      Lid sinds: 09 okt 2020

      Laatste bezoek: 10 apr 2025

    • Aanbevelingen

      Ontvangen: 4462

      Gegeven: 1414

    •    Aantal posts: 15.426

    Pharming Group reports second quarter and first half 2023 financial results

    RUCONEST® business performed strongly in 2Q 2023; continue to anticipate low single digit annual revenue growth
    Strong start to U.S. Joenja® launch during 2Q 2023; 43 patients on paid therapy and US$3.8 million revenue
    1H 2023 revenues increased 1% to US$97.4 million, compared to 1H 2022
    2Q 2023 revenues increased 9% to US$54.9 million, compared to 2Q 2022, driven by strong RUCONEST® revenues and the U.S. commercial launch of Joenja®
    RUCONEST® revenues increased 20% in 2Q 2023 to US$51.1 million, compared to 1Q 2023, but decreased 3% in 1H 2023 compared to 1H 2022
    Overall cash and cash equivalents, including restricted cash, of US$194.1 million at the end of 2Q 2023, compared to US$186.2 million at end of 1Q 2023
    Strong progress in efforts to make leniolisib available to APDS patients in key markets globally - CHMP opinion expected 4Q 2023, regulatory submissions filed in Canada, Australia, and Israel, and named patient program launched
    Leiden, The Netherlands, August 3, 2023
    Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) presents its preliminary (unaudited) financial report for the second quarter and first half ended June 30, 2023.

    Chief Executive Officer, Sijmen de Vries, commented:
    "The second quarter of 2023 was strong for Pharming. After the reimbursement disruptions experienced in the HAE market in the first quarter, RUCONEST® recovered significantly in the second quarter increasing 20% over the first quarter of 2023. Our RUCONEST® business performed well across a variety of leading revenue indicators, positioning us well for the second half of the year. RUCONEST® continues to provide a stable base for Pharming's future growth, and we continue to foresee low single digit growth in sales for the year.

    The Joenja® (leniolisib) U.S. launch got off to a strong start with the first reimbursed shipments to patients taking place in April; within two weeks of FDA approval. Our focus throughout the second quarter was enrolling identified U.S.-based APDS patients on Joenja® and working with payors on reimbursement. As of June 30, we have 60 patient enrollments and 43 patients on paid therapy, and US$3.8 million in associated revenues for the second quarter.

    We continue to make good progress in identifying additional patients with APDS in key global markets. We have now identified over 640 patients in markets including the U.S., Europe, the U.K., Japan, Canada, Australia and Israel.

    Through our regulatory, clinical, patient finding, and genetic testing efforts, we continue to make significant progress towards our goal of bringing this disease modifying treatment to adult and pediatric APDS patients worldwide.

    Pharming's progress continues to aid our patients and stakeholders as we focus on, and invest in, the long term growth of the company. I am immensely proud of our teams' many achievements in the first half of 2023."
45.610 Posts
Pagina: «« 1 ... 2088 2089 2090 2091 2092 ... 2281 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.158
AB InBev 2 5.544
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.488
ABO-Group 1 25
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.930
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 193
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.890
Aedifica 3 927
Aegon 3.258 323.203
AFC Ajax 538 7.092
Affimed NV 2 6.306
ageas 5.844 109.908
Agfa-Gevaert 14 2.074
Ahold 3.538 74.357
Air France - KLM 1.025 35.324
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.057
Alfen 16 25.488
Allfunds Group 4 1.523
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 426
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 244.238
AMG 972 134.727
AMS 3 73
Amsterdam Commodities 305 6.753
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 501
Antonov 22.632 153.605
Aperam 92 15.104
Apollo Alternative Assets 1 17
Apple 5 387
Arcadis 252 8.808
Arcelor Mittal 2.035 321.078
Archos 1 1
Arcona Property Fund 1 287
arGEN-X 17 10.377
Aroundtown SA 1 221
Arrowhead Research 5 9.757
Ascencio 1 30
ASIT biotech 2 697
ASMI 4.108 39.695
ASML 1.767 112.094
ASR Nederland 21 4.522
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 14.331
Axsome Therapeutics 1 177
Azelis Group 1 67
Azerion 7 3.463

Macro & Bedrijfsagenda

  1. 11 april

    1. Faillissementen, maart (NL)
    2. Inflatie, maart (Dld)
    3. Industriële productie, februari (VK)
    4. Handelsbalans, februari (VK)
    5. Ahold Delhaize €0,67 ex-dividend
    6. SBM Offshore ex-dividend €0,85 (bepaald op AGM 9 april)
    7. JPMorgan Chase, cijfers eerste kwartaal
    8. Morgan Stanley, cijfers eerste kwartaal
    9. Wells Fargo, cijfers eerste kwartaal
    10. BlackRock, cijfers eerste kwartaal
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda